💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Trametinib Dimethyl Sulfoxide

CHEMBL2105741 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
693.5 g/mol
LogP
—
Phase
4

Trametinib dimethyl sulfoxide is the dimethyl sulfoxide solvate form of trametinib, an allosteric MEK1/MEK2 inhibitor used in combination with BRAF inhibitors for BRAF-mutated cancers. See trametinib for complete pharmacological details. This solvate form is the pharmaceutical formulation used in approved oral tablets.

الوزن الجزيئي

693,5000 g/mol

TPSA

138,00 Ų

المجالات العلاجية

Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer

آلية العمل

Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1.C[S+](C)[O-]

                

                

                
                

                    
InChI

                    
InChI=1S/C26H23FIN5O4.C2H6OS/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34;1-4(2)3/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34);1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C28H29FIN5O5S

                    

                    
                    

                        
HBD / HBA

                        
2 / 8

                    

                    
                    

                        
الروابط القابلة للدوران

                        
5

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
41

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
Trametinib dimethyl sulfoxide is the dimethyl sulfoxide solvate form of trametinib, an allosteric MEK1/MEK2 inhibitor used in combination with BRAF inhibitors for BRAF-mutated cancers. See trametinib for complete pharmacological details. This solvate form is the pharmaceutical formulation used in approved oral tablets.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Trametinib Dimethyl Sulfoxide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2105741.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 50992434.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.